Uses of Gamma Irradiated Amniotic Membrane as an Alternative Method in Psoriasis Treatment
- Conditions
- Psoriasis
- Interventions
- Combination Product: REGE pro
- Registration Number
- NCT03440541
- Lead Sponsor
- Egyptian Atomic Energy Authority
- Brief Summary
Using of human amniotic membrane extra-cellular matrix as a topical treatment for improving Psoriasis Area and Severity Index (PASI).
- Detailed Description
Human amniotic membrane extra-cellular matrix was purchased from National center for radiation research and technology, Egypt, under commercial name REGE pro gel.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 22
- patients have psoriasis lesion
- must stop other line of treatment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description treated REGE pro Patients who received patches of REGE pro on psoriasis lesion weekly for 8 weeks
- Primary Outcome Measures
Name Time Method Histopathological improvement 6 weeks Two biopsies were taken from each patient before and at the end of the treatment. It was noted that all histological signs as munro's microabscess and the elongation of rete ridges were absent.
Scaling size decrement 2 weeks REGE pro gel decreased scaling size in patients with sever scales to moderate scale within two weeks, scaling size decrement from moderate to mild within two weeks, and from mild to complete curing within two weeks
- Secondary Outcome Measures
Name Time Method Erythema disappearing 4-6 weeks REGE pro gel gradually decreased erythema in patients within 4-6 weeks, these data were collected from applied patients by questionnaire.
Trial Locations
- Locations (1)
Amniotic tissue lab
🇪🇬Cairo, Egypt